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Abstract: There is increasing awareness of the potential for any medication that acts 
on the central nervous system to impair judgement and motor functioning, including 
driving performance. This paper reports community knowledge, perceptions and 
experience in relation to driving while taking medications. A community-based survey 
(n=316) revealed that of those who had taken any type of medication in the last 7 
days (n=193), a quarter (24%) had driven while taking a medication that they thought 
could affect them. Of those who drove for work, a quarter (26%) of the respondents 
reported that they had changed or stopped their work-related driving because they 
were taking a medication that displayed a warning label about driving. Outside of 
work, a third (35%) of the total number of respondents reported that they had done 
so. Of those who had taken any type of medication in the last 7 days, 62 were taking 
on a daily basis one or more medications classified as being likely to have a warning 
label about driving, such as sedatives, tranquilizers, antidepressants, analgesics and 
anticonvulsives. This paper will examine community knowledge, perceptions and 
experience surrounding medications and driving with particular reference to those 
persons who were taking drugs with a warning label, and the barriers to following 
such warnings.  
 
Introduction 
 
The potential for medications to impair driving is an international road safety concern 
which has arisen due to the frequency of motor vehicle use and the recognition of the 
potential for any medication that acts on the central nervous system to impair driving 
performance. Knowledge of the effect of medicinal drugs on driving risk has been 
largely derived from epidemiological and experimental studies. Results from such 
studies have found increased risk for users of benzodiazepines, sedatives, 
antihistamines, and tricyclic antidepressants, with some effects found to be 
exacerbated when the medication is combined with alcohol (Barbone et al., 1998; 
Drummer et al., 2004; Mura et al., 2003; Neutel, 1995, 1998; Ray, Fought & Decker, 
1992). This is of concern when considering the results of the 2007 National Drug 
Strategy Household Survey which showed that the majority of Australians aged 14 
years and older had consumed alcohol over the past year (AIHW, 2008).  Studies 
have demonstrated a significant increase in culpability of drivers under the influence 
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of benzodiazepines even at therapeutic concentrations (Longo et al., 2000a; 2000b). 
This is of particular concern when benzodiazepines are reported as being the most 
widely prescribed psychotropic medication in Australia, with diazepam, temazepam 
and oxazepam accounting for nearly 4% of all prescriptions by General Practitioners 
(Wain, Khong & Sim, 2007). Benzodiazepine use is known to increase with age, with 
chronic use found to be more prevalent among the elderly (Jorm et al., 2000; Simon, 
Vonkorff, Barlow, Pabiniak & Wagner, 1996).  
 
Recent findings by Mallick, Johnston, Goren and Kennedy (2007) indicate that there 
are very low levels of knowledge within the driving population of the effects of 
medications on driving, and of how much time should elapse following analgesics, 
benzodiazepines and prescription stimulant use before it is safe to drive. Compliance 
with medication instructions and cautionary advice is necessary to minimise crashes 
resulting from either the effects of the medication, illness, or unstable doses (Lococo 
& Staplin, 2006). The current Queensland medication warning system mandates the 
use of ancillary labels on medications that may cause drowsiness. At the time of data 
collection, the label shown in Figure 1 was one of the mandatory labels used in QLD 
and according to the Australian Pharmaceutical Formulary and Handbook (PSA, 
2009), it is used for medicines whose primary or secondary effect is sedation. Recent 
changes to QLD legislation mean that the display of ancillary warnings about 
potential driving impairment are no longer required if the warnings are visible on the 
manufacturer’s pack (Queensland Government, 2011). Researchers have suggested 
that increasing the noticeability of medication warnings may improve attitudes and 
adherence to warning advice about driving while taking certain medication (ICADTS, 
2001). Current research suggests there may be potential to improve Australian 
medication warning and labelling systems to improve driver awareness, attitudes and 
compliance with medication warnings (Ley, 1995; TGA, 2002). A greater 
understanding of community attitudes, knowledge and behaviour surrounding the 
effects of medications on driving, and the barriers to adhering to warnings is needed.  
 
 
 
Figure 1 Mandatory warning label used in QLD 
 
The purpose of this paper is to report our investigation, using self-report data, of 
community knowledge, perceptions and experience in relation to the impact of 
medications on driving and self-assessing personal impairment from taking 
medications. Based on previous research, those medication classes commonly 
identified as being potentially impairing and thus likely to carry a warning against 
driving, were of particular interest. For this paper, these were restricted to sedatives 
or sleeping pills, tranquilizers or other anti-anxiety, antidepressants, antihistamines or 
anti-allergic, analgesics for pain, anticonvulsives, antibiotics and other medications 
for mental health (Alvarez and Del Rio, 2000; Walsh et al., 2004; Barbone et al., 
1998; Drummer et al., 2004; Mura et al., 2003; Ray, Fought & Decker, 1992).  The 
barriers to complying with current warning labels as well as the reported reasons for 
compliance were also examined.  
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Method  
 
A telephone survey was administered by two research assistants using the online 
institutional survey software. The survey took, on average, 30 minutes to complete 
and included:  
 socio-demographic characteristics; 
 employment characteristics; 
 medication use; 
 perceived susceptibility to impairment; 
 physical and cognitive signs used to determine ‘affected’ status;  
 relative weighting of signs of impairment in making judgements about continuing 
driving or machinery use; and  
 past behaviour regarding driving or using machinery when ‘affected’. 
 
Sampling method  
 
A random sample of 690 potential participants was drawn from a representative state 
road safety survey panel. This is a large panel of participants across Queensland 
who have agreed to be recruited selectively to respond to surveys on key ongoing 
core issues. The selection criteria for the survey specified that participants must drive 
regularly and hold a valid open license. An advisory letter and hard copy of the 
survey were first mailed to participants, with the telephone survey then taking place 
within the following two weeks.   
 
Respondents 
 
A total of 316 respondents completed the telephone survey (response rate of 60%), 
40% males and 60% females. Age ranged from 18-25 to 75+ years, with the majority 
of participants falling into the 46-56 year age bracket (30%) and 57-65 year age 
bracket (29%). Under half (43%) worked on a full-time basis and a further 33% on a 
part-time basis. Thirty percent of respondents reported secondary school as their 
highest education level, 29% reported a Certificate or Diploma and another 29% a 
University qualification.   
 
 
Results 
 
Results are based on the 316 respondents who completed the survey.  
 
Driving patterns  
 
Most respondents drove on a daily basis (79%), with those remaining driving a few 
times a week.  Most (86%) were car drivers for work and of those who worked full or 
part-time, 44% reported needing to drive or ride to and from work, 17% for work 
activities and 39% both to and from work and for work activities. The average number 
of hours spent by the group driving or riding per week was 10.7 hours (range=.05-
70hrs).  
 
Medication use 
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Almost two thirds (62%, n=193) of all respondents reported taking at least one 
medication in the last 7 days. Of these, 62 were taking one or more potentially 
impairing medications on a daily basis and 61 were taking one or more potentially 
impairing medications on an occasional basis in the last 7 days (with 17 respondents 
taking one or more potentially impairing medication on a daily basis and on an 
occasional basis in the last 7 days).  
 
The majority of respondents (85%, n=266) reported taking at least one medication in 
the last 12 months. Of these, 54 had taken one or more potentially impairing 
medications on a daily basis over the year while 181 had taken one or more 
potentially impairing medications on an occasional basis in the last 12 months (with 
30 respondents reporting to have taken one or more potentially impairing 
medications on a daily basis and on an occasional basis in the last 12 months).  
 
Alcohol and Other Drugs 
 
Respondents were asked how often they consumed alcohol and had ever consumed 
other drugs. Few reported having ever consumed cannabis (18), heroin (3), ecstasy 
(4) or cocaine (4). Alcohol was reported to be consumed daily by 16% of respondents 
and occasionally by a further 68%.  
 
There was a high level of agreement with regard to the following statements: 
 Driving under the influence of alcohol is dangerous (98%) 
 Using machinery under the influence of alcohol is dangerous (98%) 
 Alcohol can increase the effects of certain medications on driving (98%) 
 Alcohol can increase the effects of certain medications on using machinery (98%)  
Knowledge 
 
Approximately half of all respondents (47%) reported that they could always tell if 
their medication was affecting their driving. A further 38% reported that they could 
sometimes tell, 12% were unsure and 3% reported that they could not tell. Of those 
who had taken a potentially impairing medication either daily or occasionally in the 
last 7 days (n=106), 55% reported that they could always tell. A very small proportion 
of the sample (3%) could not tell if they were affected.  
 
There was a high level of agreement with regard to the following statements:  
 Discontinuing any medication without the advice of your doctor can be harmful to 
your health (87%) 
 A sudden discontinuation of your medication can be harmful to your health (84%) 
 If you take more than the prescribed dose of a medication, you are more likely to 
have an accident (80%) 
 Combining medications can increase the effects of medications on driving (90%) 
 
Approximately half (52%) of respondents disagreed with the incorrect statement; 
“The risk of having an accident is weaker at the start of treatment than during long 
term treatment”.  
 
Community Perceptions 
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Respondents were asked to rate in general, how risky driving is thought to be. On a 
scale of 1-10 (1 being not risky at all and 10 being very risky) most respondents rated 
this in the mid-scale range (mean=5.7).  
 
 
 
 
Figure 2 Participant rating of how risky driving is thought to be in general 
 
Respondents were then asked to rate their own chance of being in a crash either 
caused by someone else or themselves. On a scale of 1-10 (1 being very low and 10 
being very high), most respondents rated this in the mid-scale range (mean=4.5).  
 
Figure 3 Participant rating of personal chance of being in a crash 
 
Respondents were asked to rate how impaired they thought their ability to drive 
would be after taking a medication that displayed the warning about driving shown in 
Figure 1. On a scale of 1-10 (1 being not impaired and 10 being very impaired), most 
rated this in the mid-high range (mean=6.1).  
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Figure 4 Participant rating of driving impairment if taking a medication with a warning 
 
They were also asked to rate their chance of having a crash after consuming a 
medication that displayed a warning about driving. On a scale of 1-10 (1 being very 
low and 10 being very high), most rated their chance of having a crash in the mid-
high range (mean=6.1).  
 
Figure 5 Participant rating of chance of having a crash after consuming a medication with a warning 
 
Lastly, respondents were asked to rate their chance of having a crash after 
consuming a medication that displayed a warning about driving, when affected by 
alcohol.  The affect of alcohol increased respondents rating of their chance of having 
a crash, with most rating their chance of having a crash as high or very high 
(mean=8.1) 
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Figure 6 Participant rating of chance of having a crash after consuming a medication with a warning, when affected by 
alcohol 
 
Experience 
 
The majority of respondents (74%) reported that they had never driven while taking a 
medication that they thought could affect them and around one quarter (24%) 
reported that they had. Of those who had taken at least one medication in the last 7 
days, 74% reported that they had never driven while taking a medication that they 
thought could affect them and a quarter (24%) reported that they had. Of those who 
had taken at least one medication in the last 12 months, 71% reported that they had 
never driven while taking a medication that they thought could affect them and 26% 
reported that they had. 
 
Medication warnings 
The majority of respondents (96%) had already seen a warning about driving on 
certain medication boxes. When asked if they had ever asked their doctor or 
pharmacist about the possible effects of their medication on their driving, 40% of the 
total number of respondents reported that they had. Of these, approximately half 
(57%) reported having followed this advice for their work-related driving and most 
(86%) had followed the advice for driving outside of work.  
 
Work-related driving behaviour 
Of the total number of respondents who drove for work, when asked if they had ever 
changed or stopped their work-related driving because they were taking a medication 
with a warning, 26% reported that they had, 32% reported that they had not, and the 
remaining 42% reported that it did not apply or were unsure.  
 
Of those who had taken one or more potentially impairing medications either daily or 
occasionally in the last 7 days (n=106), 28% said that they had changed or stopped 
their work-related driving. Of those who had taken one or more potentially impairing 
medications either daily or occasionally in the last 12 months (n=205), 25% said that 
they had changed or stopped.  
 
Reasons for changing or stopping their work-related driving included:  
 The physical effect that it had, i.e. drowsiness, vision impairment, light 
headedness, fatigue 
2 6 5 7 17 17
36
69 65
87
0
10
20
30
40
50
60
70
80
90
100
1 Very 
low
2 3 4 5 6 7 8 9 10 Very 
high
N
o.
   o
f re
sp
on
de
nt
s
Rating 1‐10
8 
 
 The advice given or the warning label 
 Company policy 
 Being able to get a lift with someone else 
 Feelings of safety/ not wanting to take the risk- for oneself and for others i.e. 
“Didn’t wish to put myself or anyone else in more danger” 
 Not being covered by insurance if an accident had occurred  
 
Reasons for not changing or stopping their work-related driving included: 
 Only taking the medication at night so no effects during the day 
 Didn’t think the medication was having an effect 
 Felt that the effect was manageable 
 Didn’t think about it 
 If on sick leave then no need to drive 
 Feelings of having to stay at work, i.e. “Had to work, “had to pay the bills”, and 
“had to get the job done”.  
 
Non work-related driving behaviour 
Of the total number of respondents, when asked if they had ever changed or stopped 
their non work-related driving because they were taking a medication with a warning, 
a third (35%) responded that they had.  
 
Of those who had taken at least one medication in the last 7 days (n=193), 37% had 
changed or stopped their non work-related driving and of those who had taken one or 
more potentially impairing medications either daily or occasionally in the last 7 days 
(n=106), 41% said that they had changed or stopped their non work-related driving. 
Of those who had taken one or more potentially impairing medications either daily or 
occasionally in the last 12 months (n=205), 39% said that they had changed or 
stopped their non work-related driving.  
 
Reasons for changing or stopping their non work-related driving were similar to those 
for work-related driving. Having someone who could drive for them and having to 
drive long distances were the only additional reasons provided. Reasons for not 
changing or stopping their non work-related driving were also similar to those for 
work-related driving. Having commitments, needing to get things done and not 
always having someone else to drive for them were comparable to the feelings of 
needing to ‘get the job done’ and ‘pay the bills’ at work. One interesting additional 
reason provided for not changing or stopping their non work-related driving was 
actually altering or stopping the medication use so they could continue to drive.  
 
 
Discussion 
Importantly, this study firstly highlights that this is a community wide issue affecting, 
in this sample, approximately two-thirds of the drivers - those who had taken at least 
one medication in the last 7 days and over half of these involving a medication type 
likely to warn against driving. Of further importance is the ‘moderate’ nature of both 
the reported perceived risk of driving in general and the chance of being involved in a 
crash either caused by someone else or by them self, and the perceived rating of 
driving impairment if taking a medication with a warning label.  
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While the majority of respondents had seen a warning label on certain medication 
boxes, responses were divided when it came to following the advice given to them by 
a doctor or pharmacist. Of those who had sought advice about the effects of their 
medication on their driving, a much higher proportion reported having followed this 
advice for their non work-related driving, than for their work-related driving. A similar 
pattern was found when respondents were asked whether they had ever changed or 
stopped their non work-related and work-related driving because they were taking a 
medication that carried a warning, again with a higher proportion reporting having 
changed or stopped their non work-related driving than their work-related driving.  
 
These findings suggest that while company policies and insurance issues may deter 
people in some cases from driving at work, when taking a potentially impairing 
medication, the primacy of work and/or financial pressures are holding people back 
from taking the necessary sick leave or advice when needed. As one respondent 
reported, they “had to pay the bills” and “get the job done”. Outside of work, family 
pressures and time commitments may be forcing people to keep driving, for lack of a 
more viable alternative. One person reported that they “needed to get things done” 
and that “others are not always available” to help. Notably, for some prescription 
medications, the minimum prescription time is 6-12 months, making it unfeasible to 
refrain from driving for such an extended period of time. This raises the question of 
alternative prescribing by the doctor so that the chosen medication is appropriate for 
the individual and when needed, greater responsibility placed on the consumer to 
find alternative transport if the required medication has the potential to impair driving.  
Of further concern is the perceived self-confidence when it comes to judgement of 
personal impairment, the alteration or ceasing of medication use to allow for driving 
and the perceived self-manageability of medication use. As one person reported; “if 
I’m feeling alright, and not faint headed, I just do what I have to do”.  
 
As well as the barriers to compliance, reasons for changing or stopping driving were 
examined. Results revealed that many respondents considered their own personal 
safety as well as that of other road users, and not wanting to risk having an accident, 
as important factors. Some of the factors identified as being looked for when judging 
their impairment included being told by their partner, friend or family members, 
noticing an effect during other activities and using the reactions of other drivers and 
passengers. These reasons for changing or stopping driving are important to 
consider for future research in this area.  
 
As found in previous studies, this paper shows uncertainty and lack of community 
knowledge surrounding the effects of medications on driving. While most agreed with 
statements such as “combining medications can increase the effects of medications 
on driving”, only half reported that they could always tell if they were affected. This 
uncertainty draws upon issues such as tolerance, with only half of respondents 
disagreeing with the statement “the risk of having an accident is weaker at the start of 
treatment than during long term treatment”. Encouragingly, the deleterious effects of 
alcohol on driving were overwhelmingly acknowledged by respondents, as was the 
perception that alcohol can increase the effects of certain medications on driving. 
Given the relatively high prevalence of alcohol consumption in Australia, as shown in 
the AIHW study, this is an important finding. As one respondent said; “If you have a 
zero for alcohol then you should take it [medication use] seriously”. The ongoing 
initiative in securing a cultural change to drink-driving in our society, where peer 
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intervention and support is encouraged, may offer some valuable insights into 
achieving change in the area of medications and driving. Given the age range of the 
survey sample, the finding that alcohol is consumed on a daily basis by 16% of 
respondents is also consistent with the AIHW study that reported daily alcohol 
consumption by between 9-16% of those in the 40-49, 50-59, and 60+ age brackets.  
 
 
Conclusion 
This study highlights the uncertainties and lack of community knowledge surrounding 
medications and driving. Work and personal pressure and commitments and the 
perceived manageability and acceptability of self-judgement of impairment are 
important factors to consider in future research. Due to the increased prescribing 
rates of some prescription medications and the perceived impracticality of refraining 
from driving for long periods of time, it may be important for future research to focus 
on providing more specific guidelines regarding the effects of these medications on 
driving. The effectiveness of other systems such as the highly consultative French 
model may be worth investigating. Ways to increase warning label effectiveness and 
public awareness and knowledge are also important areas for future research. 
Empirical information relating to the effects of various doses, age, body mass and 
time of taking medication is needed. Driving simulator studies have great potential to 
benefit this area of research in terms of validating the effects of medications on 
driving performance and people’s ability to self-judge impairment. Limitations relating 
to survey research such as interviewer and self-report bias and the use of a road 
safety panel-based sample are acknowledged. The potential for underreporting of the 
use of some prescription medications, alcohol and other drug use, and of those who 
drive when affected by their medication is important to note. 
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